SecProbe.io

<DOCUMENT>
<TYPE>LETTER
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>

Via Facsimile and U.S. Mail
Mail Stop 03-09

	April 1, 2005

Chemokine Therapeutics Corp.
6190 Agronomy Road, Suite 405
University of British Columbia
Vancouver, BC V6T 1Z3

RE: 	Chemokine Therapeutics Corp.
	Registration Statement on Form SB-2
      Filed March 24, 2005
Registration No. 333-123572

Dear Sir or Madam:
      This is to advise you that we have undertaken a limited
review
of the above referenced registration statement and have the
following
comment.
1. On the registration statement cover page, you state that the
prospectus contained in this registration statement shall be the
prospectus for registration statement 333-117858.  If you want to
amend the prospectus pertaining to that registration statement,
you
should amend that registration statement.  Alternatively, if the
same
shares offered under that registration statement are being offered
as
part of this registration statement, you could use this
registration
only in connection with the offering of those shares and utilize
Rule
429.  Please revise and advise.

2. The selling stockholder table contains negative beneficial
ownership in some cases.  We do not understand why.  Please revise
the selling stockholder table to comply fully with Item 507 of
Regulation S-K and name the natural persons who have sole or
shared
voting and investment power as to the securities held by each
entity
listed in the table.

3. All future amendments to the registration statement should be
signed by your principal executive officer, principal financial
officer and either your principal accounting officer or
controller.
Please revise.

*	*	*

      As appropriate, please amend your registration statement in
response to this comment.  You may wish to provide us with marked
copies of the amendment to expedite our review.  Please furnish a
cover letter with your amendment that keys your responses to our
comment and provides any requested supplemental information.
Detailed cover letters greatly facilitate our review.  Please
understand that we may have additional comments after reviewing
your
amendment and responses to our comments.

      We urge all persons who are responsible for the accuracy and
adequacy of the disclosure in the filings reviewed by the staff to
be
certain that they have provided all information investors require
for
an informed decision.  Since the company and its management are in
possession of all facts relating to a company`s disclosure, they
are
responsible for the accuracy and adequacy of the disclosures they
have made.

      Notwithstanding our comments, in the event the company
requests
acceleration of the effective date of the pending registration
statement, it should furnish a letter, at the time of such
request,
acknowledging that:

* should the Commission or the staff, acting pursuant to delegated
authority, declare the filing effective, it does not foreclose the
Commission from taking any action with respect to the filing;

* the action of the Commission or the staff, acting pursuant to
delegated authority, in declaring the filing effective, does not
relieve the company from its full responsibility for the adequacy
and
accuracy of the disclosure in the filing; and

* the company may not assert this action as a defense in any
proceeding initiated by the Commission or any person under the
federal securities laws of the United States.

	In addition, please be advised that the Division of
Enforcement
has access to all information you provide to the staff of the
Division of Corporation Finance in connection with our review of
your
filing or in response to our comments on your filing.

	We will consider a written request for acceleration of the
effective date of the registration statement as a confirmation of
the
fact that those requesting acceleration are aware of their
respective
responsibilities under the Securities Act of 1933 and the
Securities
Exchange Act of 1934 as they relate to the proposed public
offering
of the securities specified in the above registration statement.
We
will act on the request and, pursuant to delegated authority,
grant
acceleration of the effective date.

      Please contact Michael Reedich at (202) 942-1815 or to me at
(202) 942-1840.

								Sincerely,

								Jeffrey Riedler
								Assistant Director

cc:	Russell R. Frandsen, Esq.
	Squire, Sanders & Dempsey L.L.P.
	801 South Figueroa Street, 14th Floor
	Los Angeles, CA 90017

??

??

??

??

1

</TEXT>
</DOCUMENT>